exidavnemab + Placebo Comparator

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson Disease

Conditions

Parkinson Disease, Multiple System Atrophy

Trial Timeline

Oct 24, 2024 → Aug 17, 2026

About exidavnemab + Placebo Comparator

exidavnemab + Placebo Comparator is a phase 2 stage product being developed by BioArctic AB for Parkinson Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06671938. Target conditions include Parkinson Disease, Multiple System Atrophy.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease were approved

Approved (20) Terminated (3) Active (0)

Hype Score Breakdown

Clinical
12
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06671938Phase 2Active

Competing Products

20 competing products in Parkinson Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
19
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
LY4006896 + PlaceboEli LillyPhase 1
36
ATH-1017 + PlaceboLeonaBioPhase 2
17
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
35
Mirabegron + PlaceboAstellas PharmaApproved
43
E2007EisaiPhase 3
32
ARICEPTEisaiPhase 3
40
PerampanelEisaiPhase 3
32
GPI 1485EisaiPhase 2
35
E2007EisaiPhase 3
40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
40
Equfina 50 mgEisaiPre-clinical
26
EqufinaEisaiPre-clinical
26
perampanel + placeboEisaiPhase 2
27
Lemborexant + placeboEisaiApproved
50
Placebo + E2007 + E2007EisaiPhase 3
32
Safinamide MesilateEisaiApproved
43
E2007 + E2007 + E2007EisaiPhase 2
35
E2007EisaiPhase 2
35